1. Annual report 2024
  2. Research
  3. GRECAP

GRECAP

Cardiovascular research group in primary care

The group is made up of seven family doctors, a doctor and a graduate in Statistics, all working in Barcelona. 44% of its members are women. There are four doctors, two of whom are women and one more is finishing her doctoral thesis. The group has a recognized track record and was accredited as consolidated by AGAUR in 2021 (2021 SGR 01417). Within the group, several doctoral theses have been defended and three others are currently in progress.

The group's lines of work are specifically:
1. Heart Failure in Primary Care: Knowledge, attitudes and skills of patients and professionals regarding the management of heart failure. Evaluation of interventions
2. High blood pressure and cardiovascular risk
3. Primary and secondary cardiovascular prevention
 

Group projects

  • Prognostic models of morbidity and mortality of stable and decompensated heart failure in Primary Care. (PREDOC_ECO-23/8). ICS - Catalan Institute of Health. 2024-2029. PI: Maria Antònia Pou Giménez,Victoria Cendrós Cámara.
  • Prognostic value of 24-hour outpatient blood pressure monitoring on the incidence of cardiovascular events in patients undergoing primary cardiovascular prevention. (PREDOC_ECO-19/5). ICS - Catalan Institute of Health. 2020-2024. IP: Clara Puig Pera.
  • Algorithm that calculates your risk of cardiovascular event in the next 5 years. PI: Ernest Vinyoles Bargalló
  • Very short-term prognostic stratification of decompensated heart failure in primary care: HEPHAESTUS 3.7 Score. (PI23/01422). Carlos III Health Institute. 2024-2026. PI: José María Verdú Rotellar.
  • A multi-center, randomized, double-blind, parallel-group, 20-week dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with resistant hypertension. (CXXB750B12201). Novartis Farmacéutica, S.A. 2023IP: Ernest Vinyoles Bargalló.
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Participants With High-Risk for Disease Progression. (GS-US-611-6273). Gilead Sciences, S.L. 2023IP: Ernest Vinyoles Bargalló. - Relationship between the H2PEF SCORE and the morbidity and mortality of patients with heart failure with ejection fraction. ICS - Institut Català de la Salut. 2022-2025. PI: José María Verdú Rotellar.
  • PEEADE-SIDIAP Project: Long-term cardiovascular follow-up by SIDIAP of a cohort without cardiovascular disease representative of the population over 64 years of age. Consortium Center for Biomedical Research in RED (CIBER). 2022-2025. PI: José María Verdú Rotellar.
  • Orthostatic Hypertension, Ambulatory Pressure and Hypertensive Phenotypes. 2022-2026. PI: Ernest Vinyoles Bargalló.
  • External validation of the risk algorithm of the project "Prognostic value of 24-hour outpatient blood pressure monitoring on cardiovascular morbidity and mortality in patients in primary cardiovascular prevention". ICS - Catalan Institute of Health. 2022-2025. PI: Ernest Vinyoles Bargalló.
  • An international multicenter, randomized, double-blind, placebo-controlled trial of the safety and efficacy of anti-coronavirus hyperimmune intravenous immunoglobulin for the treatment of adult outpatients in early stages of COVID-19. (INSIGHT 12). University of Minnesota. 2021IP: Ernest Vinyoles Bargalló.
  • Epidemiology of Heart Failure in Catalonia: a cohort study. Novartis Pharma AG. 2015IP: Miguel Angel Muñoz Pérez.
  • Ultrasound reproducibility of LVH voltage criteria and ST-T segment alterations. ICS - Catalan Institute of Health. 2008-2025. PI: Ernest Vinyoles Bargalló.

Group Publications

  • Guimarães P, Keller A, Böhm M, Lauder L, Fehlmann T, Ruilope LM et al. Artificial Intelligence-Derived Risk Prediction: A Novel Risk Calculator Using Office and Ambulatory Blood Pressure. Hypertension. 2025; 82(1):46-56. PMID:38660828.
  • Belahnech Y, Ródenas Alesina E, Muñoz MA, Verdu Rotellar JM, Sao Avilés A, Urio Garmendia G et al. Systematic Coronary Risk Evaluation 2 for Older Persons: 10 years risk validation, clinical utility, and potential improvement. Eur J Prev Cardiol. 2024; PMID:39657030.
  • De la Sierra A, Ruilope LM, Staplin N, Gorostidi M, Vinyoles E, Segura J et al. Resistant Hypertension and Mortality: An Observational Cohort Study. Hypertension. 2024; 81(11):2350-2356. PMID:39247961.
  • De la Sierra A, Staplin N, Ruilope LM, Gorostidi M, Vinyoles E, Segura J et al. A blunted nocturnal blood pressure decline is associated with all-cause and cardiovascular mortality. J Hypertens. 2024; 42(7):1197-1202. PMID:38477142.
  • Verdu Rotellar JM, Calero E, Duran J, Navas E, Alonso S, Argemí N et al. Impact of malnutrition on the quality of life in older patients with advanced heart failure: a cohort study. Rev Clin Esp (Barc). 2024; 224(2):105-113. PMID:38280424.
  • Baenas I, Camacho Barcia L, Granero R, Razquin C, Corella D, Gomez Martinez C et al. Association between type 2 diabetes and depressive symptoms after a 1-year follow-up in an older adult Mediterranean population. J Endocrinol Invest. 2024; 47(6):1405-1418. PMID:38218741.
  • Verdu JMJM, Cendros V, Munoz MA, Casacuberta JM, Juan J, Navas E et al. Usefulness of the H2PEF score in the stratification of patients with a diagnosis of heart failure with preserved ejection fraction in primary care. Eur. J. Heart Fail. 2024;2663-63.
  • Artero MP, Salgueiro MC, Borrell JT, Bonet JR, Nadal OR, Camps MB et al. Comparison between 2021 national hypertension guidelines and 2023 european society of hypertension guidelines. J Hypertens. 2024; 42
  • Borrell JT, Camps MB, Nadal OR, Salgueiro MC, Artero MP, Nicolau MV et al. Hypertension gaming: a new divulgation method for guidelines. J Hypertens. 2024; 42
Anar a l'inici